Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07472413 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project

Name: Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project — clinical trial record (NCT07472413)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorUniversity of Miami

Started2026-09-01

View on ClinicalTrials.gov ↗

Amendment history

2026-07-09

Study Status v1

Start date2026-07-01→2026-09-01

2026-03-11

Original filing

University of Miami

241 trials monitored

See 29 trials at risk

Multiple Sclerosis

987 trials monitored

See 31 trials at risk

The purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy.

Trial Details

NCT Number	NCT07472413
Lead Sponsor	University of Miami
Conditions	Multiple Sclerosis
Enrollment	60 participants
Start Date	2026-09-01
Primary Completion	2028-07-01 (estimated)
Study Completion	2028-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-13